Developed by smoking giants Philip Morris International, IQOS devices heat tobacco at a lower temperature instead of burning it, reducing the release of harmful toxins
However, mortality rates are about 1.9 times higher in men than in women.[1] It is estimated that there will be 59,660 new cases of oral cavity and oropharynx cancer diagnosed in the United States in 2025 and 12,770 deaths due to these diseases.[2] Rates of oral cavity cancer vary greatly across the world, primarily because of differences in alcohol use, tobacco use, and betel-quid chewing and the products chewed.[3] Although localized cancers of the oral cavity and oropharynx have an excellent anticipated 5-year survival rate of about 87.5%, only 26.4% of these cancer cases are diagnosed at this stage.[1] The overall 5-year relative survival rate for patients with cancers of the oral cavity and oropharynx combined is only 69%.[2] However, the 5-year relative survival rate is much lower in Black patients (57%) than in White patients (71%).[2] Additionally, the 5-year survival rate varies greatly by cancer site, with 52.1% survival among patients with cancer on the floor of the mouth and 73.8% survival among patients with cancer in the oropharynx and tonsil.[4] Hypopharyngeal cancer Hypopharyngeal cancers are rare, with approximately 2,500 new cases diagnosed in the United States each year and an annual incidence of 0.6 cases per 100,000 persons.[5] The 5-year survival rate for hypopharyngeal cancer is 35%.[5] New cases have been falling an average of 2% per year over the last 20 years.[5] This has been attributed to a reduction in cigarette smoking
Retrieved on 2026, July 27 from
Other Bay Area cities, including Oakland and San Jos, have passed similar legislation
